Market Assessment, Breast Cancer Current Treatment EU5 2016 Report

Breast cancer requires a multidisciplinary treatment approach that incorporates surgery, radiotherapy, chemotherapies, and targeted therapies. Treatment decisions are influenced by disease stage, resectability, and HER2 and HR status. HER2-targeting therapy is the cornerstone of treatment regardless of HR status. This analysis provides insight on the current use of approved therapies for HER2-positive breast cancer in the EU5 and on factors driving physicians’ prescribing decisions.

Back to all Market Assessment reports

Contact us

Investors

Careers

Login

Breast Cancer | Current Treatment | EU5 | 2016

Related Market Assessment Reports

Non-Small-Cell Lung Cancer – Current Treatment – Detailed, Expanded Analysis (US)

Migraine – Current Treatment – Detailed, Expanded Analysis (EU5)

Breast Cancer – Unmet Need – Detailed, Expanded Analysis: Advanced Or Metastatic HER2-Positive Breast Cancer (US/EU)

Heart Failure – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Heart Failure – Preserved Ejection Fraction (US)

Male Hypogonadism – Current Treatment – Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis – Male Hypogonadism (Low Testosterone) (US)